The HIV Cure Research Agenda: The Role of Mathematical Modelling and Cost-Effectiveness Analysis.
作者： Cristina Possas , Steven Deeks , AnnaLaura Ross , Katherine L. Rosettie , Michele Di Mascio
DOI: 10.1016/S2055-6640(20)30929-8
关键词:
摘要: The research agenda towards an HIV cure is building rapidly. In this article, we discuss the reasons for and methodological approach to using mathematical modeling cost-effectiveness analysis in agenda. We provide a brief description of proof concept current directions research. then review types clinical economic evaluations, including cost analysis, cost-benefit analysis. describe use early epidemic as well era combination antiretroviral therapy. highlight novel methodology Value Information its potential role planning trials. close with recommendations
fiocruz.br
harvard.edu参考文章(52)
Joseph S. Pliskin, Eve Wittenberg, Milton C. Weinstein, John B. Wong, M. G Myriam Hunink, Michael F. Drummond, Paul P. Glasziou, Decision Making in Health and Medicine: Integrating Evidence and Values ,(2014)
Steven G. Deeks, Jason D. Barbour, Robert M. Grant, Jeffrey N. Martin, Duration and predictors of CD4 T-cell gains in patients who continue combination therapy despite detectable plasma viremia. AIDS. ,vol. 16, pp. 201- 207 ,(2002) , 10.1097/00002030-200201250-00009
Karina M. Butler, Patrick Gavin, Suzie Coughlan, Annette Rochford, Sinead Mc Donagh, Orla Cunningham, Hannah Poulsom, Sarah A. Watters, Nigel Klein, Rapid Viral Rebound After 4 Years of Suppressive Therapy in a Seronegative HIV-1 Infected Infant Treated From Birth The Pediatric Infectious Disease Journal. ,vol. 34, pp. e48- e51 ,(2015) , 10.1097/INF.0000000000000570
Rodica Stan, John A. Zaia, Practical Considerations in Gene Therapy for HIV Cure Current Hiv\/aids Reports. ,vol. 11, pp. 11- 19 ,(2014) , 10.1007/S11904-013-0197-1
Milton C. Weinstein, Sue J. Goldie, Elena Losina, Calvin J. Cohen, John D. Baxter, Hong Zhang, April D. Kimmel, Kenneth A. Freedberg, Use of Genotypic Resistance Testing To Guide HIV Therapy: Clinical Impact and Cost-Effectiveness Annals of Internal Medicine. ,vol. 134, pp. 440- 450 ,(2001) , 10.7326/0003-4819-134-6-200103200-00008
Kenneth A Freedberg, Julie A Scharfstein, George R Seage III, Elena Losina, Milton C Weinstein, Donald E Craven, A David Paltiel, The Cost-effectiveness of Preventing AIDS-Related Opportunistic Infections JAMA. ,vol. 279, pp. 130- 136 ,(1998) , 10.1001/JAMA.279.2.130
Paul Trueman, Mike Youle, Caroline Sabin, Alexander Miners, Eduard Beck, The Cost-Effectiveness of Triple Nucleoside Analogue Therapy Antiretroviral Regimens in the Treatment of HIV in the United Kingdom Hiv Clinical Trials. ,vol. 1, pp. 27- 35 ,(2000) , 10.1310/P52N-KXJH-1945-UX7X
Rodolphe Thiébaut, Margaret T. May, Mathematical modelling of HIV prevention intervention. AIDS. ,vol. 27, pp. 475- 476 ,(2013) , 10.1097/QAD.0B013E32835C1509
James Kahn, E Marseille, MJ Giganti, A Mwango, A Chisembele-Taylor, L Mulenga, M Over, JG Kahn, JSA Stringer, Taking ART to Scale: Determinants of the Cost and Cost-Effectiveness of Antiretroviral Therapy in 45 Clinical Sites in Zambia PLoS ONE. ,vol. 7, pp. e51993- ,(2012) , 10.1371/JOURNAL.PONE.0051993
Asier Sáez-Cirión, Charline Bacchus, Laurent Hocqueloux, None, Post-Treatment HIV-1 Controllers with a Long-Term Virological Remission after the Interruption of Early Initiated Antiretroviral Therapy ANRS VISCONTI Study PLoS Pathogens. ,vol. 9, pp. e1003211- ,(2013) , 10.1371/JOURNAL.PPAT.1003211